|
Telik, Inc. of Palo Alto, CA is an innovative biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company’s most advanced investigational drug candidates in clinical development are TELINTRA® (Ezatiostat HCl, TLK199) for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA® (Canfosfamide HCl, TLK286) for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik’s product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates.
 Eighth Annual Needham Life Sciences Conference
June 10, 2009
10:30 am EDT (7:30 am PDT)
Click here for the webcast.
2008 Annual Report
2009 Proxy Statement
June 4, 2009
Telik Announces Presentation and Webcast at Needham Life Sciences Conference
May 31, 2009
Telik Presents Results at ASCO from ASSIST-5 Trial of TELCYTA in Platinum Refractory and Resistant Ovarian Cancer
|
